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Purpose: The purpose of this study was to evaluate the merit of polytetrafluoroethylene 
(PTFE) extensions and interpositions for the management of failing infrainguinal vein 
bypass grafts. 
Methods: The treatment of 133 failing vein grafts in 125 patients over a 10-year period was 
retrospectively reviewed. Twenty-two graft-threatening lesions were detected in patients 
who did not have a usable autogenous vein conduit as determined by preoperative and 
intraoperative evaluations. A PTFE extension or interposition graft was used for the 
necessary reconstruction i  all cases. 
Results: Ten lesions were within the vein graft, 11 were proximal to the graft in the femoral 
or popliteal artery segments, and one was distal to the graft in the popliteal artery. The 
treatment of these lesions included 19 extensions and three mid graft interpositions. The 
vein graft lesions developed significantly sooner (mean 10.6 -+ 2.5 months) after the 
bypass (p < 0.05) than the arterial lesions (mean 28.0 + 6.1 months). The 3-year 
cumulative secondary patency rate for these vein grafts treated with PTFE extensions or 
interpositions was 84% + 8%. This was not significantly different from the 3-year 
cumulative secondary patency rate for vein grafts treated with vein extensions or 
interpositions atour institution over the same time period (82% --. 10%). The 3-year limb 
salvage rates were 95% and 89%, respectively. 
Conclusions: These results indicate that PTFE extensions and interpositions can be used 
successfully to maintain the patency of failing vein grafts and may serve to prolong limb 
salvage in patients without any usable autogenous vein. Early reintervention with a PTFE 
conduit in this difficult group of patients is appropriate to salvage a failing vein graft. 
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Advances in vascular diagnosis and intervention 
have resulted in improved primary and secondary 
patency rates of lower extremity vein bypass grafts 
with an associated improvement in limb salvage 
rates. 1 However, vein grafts have a steady rate of 
attrition and thrombosis as a result of  the develop- 
ment of  graft and anastomotic lesions or progression 
of atherosclerotic disease proximal or distal to the 
grafts. 2Stenotic lesions that can lead to graft throm- 
bosis develop in 11% to 3 3 % of all vein grafts and are 
usually detected within 24 months of the initial 
procedure if a surveillance protocol is closely fol- 
lowed. 2-13 These lesions are also the most common 
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cause of threatened or failing vein grafts. Progressive 
atherosclerotic arterial lesions proximal or distal to a 
vein graft usually occur more than 2 years after the 
initial intervention and account for 20% to 50% 0fall 
lesions responsible for failing vein grafts. 2'12,1s 
If left untreated these arterial or vein graft lesions 
will often lead to graft thrombosis and recurrent 
ischemic symptoms. Vein graft revisions (patch 
angioplasties, extensions, or interpositions) with a 
segment of autogenous vein are generally believed to 
be the best treatment for vein graft or progressive 
atherosclerotic arterial occlusive l sions. 13-16 Ifa good 
autogenous vein conduit is not readily available, 
other alternatives need to be considered. Balloon 
angioplasty is a reasonable option for focal inflow or 
outflow arterial esions and for selected focal vein 
graft lesions. 2'9,16 For all other arterial or vein graft 
lesions, an alternative conduit is necessary, because 
the results of angioplasty of long vein graft lesions 
(> 1.5 cm) are poor, 1416 and angioplasty of long 
( > 5 cm) infrainguinal rterial lesions has not proven 
to be effective. 
Over the past decade we have used polytetraflu- 
oroethylene (PTFE) grafts as extensions or interpo- 
sitions in these circumstances. This report describes 
our experience and results with these PTFE grafts for 
the treatment offailing vein bypasses in patients who 
did not have a usable autogenous vein conduit. 
PATIENTS AND METHODS 
Between January 1, 1984 and December 31, 
1994, 133 failing vein grafts in 125 patients were 
treated at our institution. After discharge from the 
hospital, all patients who underwent infrainguinal 
vein bypasses were observed every 2 weeks for the 
first month, every 3 months for the first year, and 
every 3 to 6 months thereafter. Noninvasive xami- 
nations (ankle brachial indexes and pulse volume 
recordings) were performed periodically and when- 
ever graft deterioration or failure was suspected by 
changes in the history, pulse examination, orphysical 
findings. Duplex ultrasonography was performed 
only sporadically during the first 4 years of this study 
but was routinely done with the other noninvasive 
examinations over the last 6 years. Patients with 
objectively altered noninvasive evaluations were sub- 
jected to complete lower extremity arteriography, 
which confirmed the patency of all failing vein by- 
passes and the location of the graft-threatening le- 
sions. Twenty-two graft-threatening lesions were de- 
tected in 19 patients who did not have a usable autog- 
enous vein conduit for the proposed corrective 
procedure. One patient had bilateral interventions, 
and two grafts were revised twice to account for the 
22 lesions in 19 patients. Nine were detected primar- 
ily by physical examination and 13 by routine duplex 
ultrasonography performed in the absence of any 
changes in the patient's pulse status or physical find- 
ings. Sixty-eight percent (13 of 19) of the patients 
had a previous ipsilateral lower extremity arterial by- 
pass other than the failing graft, 42% (8 of 19) had 
previous contralateral lower extremity arterial by- 
passes, 42% (8 of 19) had previous coronary artery 
bypass grafting, 15% (3 of 19) had a previous con- 
tralateral major amputation limiting the source of 
venous conduits, and 11% (2 of 19) were undergoing 
hemodialysis for end-stage renal disease precluding 
the use of upper extremity veins. Any possible sources 
of autogenous vein for the proposed bypass were 
evaluated before operation with venous duplex ultra- 
sonography and during operation by surgical explo- 
ration of the potential veins. All graft extensions and 
interpositions were performed with a PTFE conduit 
that was 6 mm in diameter. After the intervention for 
the failing state, these patients were closely moni- 
tored by use of the technique and schedule used after 
the primary bypass. 
There were four men and 15 women in the group. 
Limb-threatening ischemia was the indication for the 
initial bypass in all patients. The patients were 
monitored for 5 to 101 months (mean 40 months) 
from the initial procedure and from 1 to 77 months 
(mean 25 months) after the reintervention for the 
failing state. Over the same time period, 34 vein 
grafts (in 33 patients) were treated for the failing state 
with vein used as a conduit. There were 17 men and 
16 women in this group. The patients were moni- 
tored for 3 to 96 months (mean 37 months) from the 
initial procedure. 
Data collection and analysis. Data were ob- 
tained from a registry maintained on an IBM micro- 
computer (IBM Corporation, Armonk, N.Y.) with a 
relational database (DataEase International, Trum- 
bull, Conn.) specifically adapted for the monitoring 
of patients undergoing vascular interventions. The 
secondary patency, extended patency, and limb 
salvage rates were calculated by use of the cumulative 
life-table method. The extended patcncy rates were 
calculated from the time of the first intervention for 
the failing state to the most recent endpoint. The 
results are reported in accordance with the guidelines 
established by the Ad Hoc Committee on Report- 
ing Standards, Society for Vascular Surgery/North 
American Chapter, International Society for Cardio- 
vascular Surgery.17 Life-tables were compared by use 
of the log rank test. Comparison of treatment group 
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Fig. 1. A, Arteriogram of 67-year-old woman who had previous bilateral ower extremity 
revascularizations for limb-threatening ischemia and multiple coronary artery bypasses. The 
patient was diagnosed with failing femoropopliteal bypass because of 20 to 25 cm diseased 
segment of vein graft 10 months after procedure. B, 35-cm proximal extension was performed 
with PTFE; the graft is patent without any significant lesions 2 years after revision. 
presentations (vein vs arterial esions) was performed 
with the Student  test analysis. Statistical significance 
was assumed at the 95% confidence level (p < 0.05). 
RESULTS 
Twenty failing vein grafts in 19 patients were 
revised by use of PTFE extensions or interpositions. 
These included six femoropopliteal, seven femoro- 
distal, and seven popliteal-to-distal grafts. Nineteen 
grafts were reversed greater saphenous vein conduits, 
and one graft was a nonreversed translocated greater 
saphenous vein conduit. A total of 22 graft-threat- 
ening lesions in 19 patients were diagnosed by 
physical examination or duplex scanning, confirmed 
by arteriography, and treated during the study 
period. Ten lesions were within the vein graft, 11 
were proximal to the graft in femoral (n = 9) 
or popliteal (n = 2) artery segments and one 
was distal to the graft in the popliteal artery. The 
vein graft lesions developed significantly sooner 
(mean 10.6 + 2.5 months) after the original opera- 
tion (p < 0.05) than the arterial lesions (mean 
28.0 +_ 6.1 months). 
These lesions were treated with 19 extensions to 
bypass a diseased segment of vein graft or native 
artery and three mid graft interpositions (Fig. 1). 
Two of the three mid graft interpositions were patent 
at the end of follow-up (mean 19 months). The 
PTFE grafts used to bypass these long, graft- 
threatening lesions measured from 12 to 40 cm 
(mean 24 cm). The 3-year cumulative secondary 
patency rate was 84% + 8% (Table I, Fig. 2), 
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Fig. 2. Secondary patency rates of failing vein grafts treated with PTFE or vein segment 
extensions and interpositions. The secondary patency rate at 36 months was 84% for PTFE 
reconstructions (square) and 82% for vein reconstructions (circle). Error bars represent the 
standard error at each interval. 
Table I. Secondary patency rates of  failing vein grafts treated with PTFE extensions 
and interpositions 
Cumulative SE of cumulative 
Interval No. of grafts No. of grafls Interval failure Interval patency patency rate patency rate 
(mos.) at risk withdrawn rate (%) rate (%) (%) (%) 
0-1 20 0 0 100 100 0 
1-3 20 0 0 100 100 0 
3-6 20 0 1 95 95 5 
6-9 19 0 0 100 95 5 
9-12 19 0 0 100 95 5 
12-15 19 0 0 100 95 5 
15-18 19 0 0 100 95 5 
18-21 19 1 1 95 90 7 
21-24 17 i 1 94 84 8 
24-27 15 1 0 100 84 8 
2740 14 0 0 100 84 8 
30-33 14 1 0 100 84 8 
33-36 13 2 0 100 84 8 
whereas the 18-month cumulative xtended patency 
rate of these vein grafts from the time of the PTFE 
extension or interposition was 80% _+ 10%. The 
3-year limb salvage rate was 95% + 6%. There were 
no deaths within 30 days of the intervention for the 
failing state in this group of patients, and the 
complication rate was 5%. 
Over the same period, 34 grafts in 33 patients 
were revised with vein conduits (10 femoropopliteal, 
16 femorodistal, and 8 popliteal-distal). Twenty-five 
were reversed saphenous vein, four in situ vein, three 
nonreversed translocated vein, and two cephalic vein. 
The lesions were treated with 16 proximal extensions, 
10 distal extensions, and 8 interposition grafts. The 
3-year cumulative secondary patency rate for these 
grafts was 82% e 10% (Table II). The 3-year limb 
salvage rate was 89% _+ 10%. 
No significant differences in the 3-year secondary 
patency and limb salvage rates were found between 
the vein grafts treated with PTFE extensions or 
interpositions and the vein grafts treated with vein 
extensions or interpositions (Fig. 2). 
D ISCUSSION 
The diagnosis and early treatment of  graft- 
threatening lesions associated with vein grafts has led 
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Table II. Secondary patency rates of failing vein grafts treated with vein extensions 
and interpositions 
Cumulative SE of cumulative 
Interval No. of grafts No. of grafls Interval failure Interval patency patency rate patency rate 
(mos.) at risk withdrawn rate (%) rate (%) (%) (%) 
0-1 34 0 0 100 100 0 
1-3 34 1 1 97 97 3 
3-6 32 I 1 97 94 4 
6-9 30 4 1 96 91 5 
9-12 25 0 0 100 91 6 
12-15 25 2 0 100 91 6 
15-18 23 2 0 100 91 6 
18-21 21 0 1 95 86 7 
21-24 20 1 1 95 82 8 
24-27 18 3 0 100 82 8 
27-30 15 0 0 100 82 9 
30-33 15 2 0 100 82 9 
33-36 13 0 0 100 82 10 
to improved secondary patency rates and prolonged 
limb salvage rates. 2qa It is essential to identify vein 
grafts while in the failing state because their man- 
agement is different, and the ultimate outcome is 
significantly better than that of occluded grafts, s'6 
Our group has shown acceptable r sults with percu- 
taneous balloon angioplasty for the treatment of 
short inflow and outflow arterial esions 2 and for 
single, short ( < 1.5 cm) vein graft stenoses) 6 How- 
ever, the reinterventions forthe failing state generally 
involve correction of a defect hat requires a patch, 
graft extension, or graft interposition with a segment 
of autogenous vein. 
Frequenty in these patients the contralateral 
saphenous vein has been used previously for a 
coronary artery bypass or a contralateral lower 
extremity reconstruction. I  addition, because of the 
increased recognition by vascular surgeons that 
reoperation is appropriate for limb-threatening isch- 
emia as a result of failure of primary lower limb 
bypasses, 18a9 a growing proportion of patients are 
without a usable segment of autogenous vein to 
revise a failing graft. The lesser saphenous vein has 
been used for infrainguinal bypasses 2°,21 and inter- 
positions or extensions to revise failing graft¢ awith 
reasonable success in selected patients. Unfortu- 
nately, in many patients this conduit is diseased, too 
small ( < 2.5 mm in diameter), or not available. Arm 
vein can also be used, but with lower patency rates 
than those of other venous conduits when used for 
initial bypass grafts 2~ or extensions of failing vein 
grafts.la In addition, these conduits often have several 
sclerotic or recanalized segments and may be of 
inadequate l ngth for the proposed procedure, re- 
quiring mukiple, composite vein segments which 
have worse patency rates than single segments. 21 
Our results with PTFE used for vein graft 
extensions and interpositions (3-year secondary pa- 
tency rate of 84%; 18-month extended patency rate 
of 80%) suggest that these grafts can be successfully 
used to maintain the patency of failing vein grafts. In 
addition, these results are comparable with the 3-year 
secondary patency rate (82%) (Fig. 2) for failing vein 
grafts that are treated with vein reconstructions. The 
improved results in this small group of patients who 
were treated with PTFE graft revisions may have 
been partially due to their selection. The graft- 
threatening lesions were treated promptly, and these 
patients had not developed progressive arterial oc- 
clusive disease of their outflow vessels, making them 
more likely to have a good outcome. Furthermore, 
the 3-year limb salvage rate in this group of failing 
grafts (95%) compares favorably with the 3-year limb 
salvage rate of patients treated with vein reconstruc- 
tions (89%). 
After revision, these grafts can be considered 
composite grafts of a new 6 mm PTFE segment and 
an arterialized segment of vein graft. The results of 
composite grafts of PTFE and vein reported in the 
literature are variable. Femoral to below-the-knee 
composite bypasses have 3-year patency rates of 45% 
to 50%, 22"z3 whereas femoropopliteal-distal compos- 
ite sequential bypass grafts have 2-year patency rates 
of 80% 24,25 and 3-year patency rates of 48%.  26 A 
composite graft of PTFE and a functioning segment 
of vein could be expected to have even better patency 
rates than initial composite grafts because the remain- 
ing venous portion of this composite graft has al- 
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ready been shown to be a good, functional arterial 
conduit. 
The alternative of allowing a failing graft to 
thrombose instead of using a PTFE graft to revise it 
is not appropriate. Efforts to manage thrombosed 
vein grafts with thrombectomy and graft revision 
have been discouraging, with 1-year patency rates of 
only 49%. 6 In addition, the results, of thrombolytic 
therapy in conjunction with revision of the underly- 
ing lesion that leads to graft failure have also been 
discouraging to date. 27-32 In our experience, throm- 
bosed vein grafts treated with thrombolytic therapy 
have limited long-term patency rates, even when a 
correctable, causative lesion is found. Endothelial 
injury and remodeling during the period of throm- 
bosis may accotmt for these poor results. 
Secondary or tertiary arterial reconstructions are 
the other alternative for the treatment of vein graft 
thrombosis in patients with recurrent limb-threat- 
ening ischemia. These secondary reconstructions 
have higher morbidity and mortality rates than 
procedures for failing grafts, s,6 In addition, the 
secondary reconstruction ecessary in a patient who 
had a previous bypass for limb salvage is usually a 
femorotibial bypass. These distal reconstructions 
with PTFE, although sometimes uccessful, have a 
worse long-term patency rate than comparable vein 
graft bypasses. 19 
These early results indicate that supplementary 
PTFE extensions or interposition grafts can be used 
successfully to maintain the patency of a failing vein 
graft and may serve to prolong limb salvage in 
patients without any usable autologous vein. Fur- 
thermore, the other options available after graft 
thrombosis, including graft thrombectomy and revi- 
sion, thrombolysis and graft revision or secondary 
prosthetic bypass procedures, are inferior alternatives 
in this difficult group of patients. Close postoperative 
surveillance and aggressive, early, surgical reinterven- 
tion with a PTFE extension or interposition graft 
rather than conservative, nonoperative treatment or 
suboptimal angioplasty are indicated when a failing 
vein graft is detected and no acceptable autogenous 
vein is available. 
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DISCUSSION 
Dr. Walter J. McCarthy (Chicago, Ill.). The authors 
have brought o our attention the difficult group of patients 
who require venous conduit but do not have it available for 
bypass. Over the last decade, while treating 133 failing vein 
grafts, this situation developed only 22 times (twice per 
year). These numbers emphasize the authors' diligent 
search for venous conduit, including the use of duplex 
scanning, before selecting a PTFE extension graft. 
The justification for use of this material must lie in the 
resulting patency rate, which leads me to my first question. 
The authors have compared the 3-year secondary patency 
rate of the PTFE extension graft group with the secondary 
patency rate of all the vein grafts in their series and found 
them to be similar. Use of this control group results in a 
selection bias, as is acknowledged. The problem results 
from failing but patent grafts being compared with a group 
in which some grafts have already thrombosed. The proper 
control group would be the cohort of failing grafts 
resurrected with venous conduit. Have the authors looked 
at the secondary patency in this group? 
Do the authors recommend warfarin (Coumadin) for 
these patients? Do they ever use PTFE as a patch material 
for a stenotic vein graft? 
I enjoyed this study, although I do not believe that it 
proves that PTFE extensions are equal to venous repair; 
however, it does demonstrate an acceptable patency rate 
when venous conduit is not available. 
Dr. Luis A. Sanchez. In answer to your first question, 
the results were similar when we compared our failing 
grafts that were repaired with PTFE with the grafts that 
were repaired using a venous patch, interposition or 
extension. Our group of patients that fit into this category 
was relatively small, since over the last decade we enthusi- 
astically used angioplasty for the treatment of vein graft 
lesions. As our results were poor except for short vein graft 
lesions, we have since moved away from this view. 
Regarding the use of Coumadin, if a graft became a 
composite femoropopliteal graft, most of these patients 
were put back on aspirin and persantine and then closely 
followed. If a patient had a distal bypass or the runoff was 
poor, they were started on Coumadin. We believe that the 
majority of patches do not work very well. There are data 
in the literature which suggest that the results of patches are 
worse than those for interpositions or extensions, prefer- 
ably performed with a venous conduit. 
We are trying to emphasize the importance of repairing 
these failing grafts, since the options are limited if they 
thrombose. If a venous conduit is not available for the 
repair, a prosthetic conduit should be used in an attempt to 
maintain the patency of the graft. 
